The European Commission has granted conditional marketing authorization for the CD20xCD3 T-cell engaging bispecific antibody Lunsumio (mosunetuzumab), developed by Swiss pharma giant Roche (ROG: SIX).
Lunsumio is indication for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. Lunsumio is an off-the-shelf therapy that is readily available, so people do not have to wait to start treatment. This follows a positive recommendation from the European Medicines Agency’s human medicines committee (CHMP) in April.
Mizuho Securities analyst Salim Syed has previously forecast peak sales of more than $1 billion for mosunetuzumab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze